New hope for advanced kidney cancer patients in early drug trial
NCT ID NCT06234605
Summary
This early-stage study is testing the safety and best dose of a new drug, HC-7366, when given alongside an approved kidney cancer drug, belzutifan. It will enroll about 80 adults with advanced kidney cancer that has spread or cannot be removed by surgery. The main goal is to find the highest dose patients can tolerate without severe side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
Contact Email: •••••@•••••
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
Contact Email: •••••@•••••
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
Contact Email: •••••@•••••
-
HealthPartners Cancer Research Center
RECRUITINGSaint Paul, Minnesota, 55101, United States
Contact Email: •••••@•••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Email: •••••@•••••
-
Providence Cancer Institute
RECRUITINGPortland, Oregon, 97213, United States
Contact Email: •••••@•••••
-
Rocky Mountain Cancer Centers, LLP
RECRUITINGLone Tree, Colorado, 80124, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Swedish Medical Center
RECRUITINGSeattle, Washington, 98104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Texas Oncology
RECRUITINGDallas, Texas, 75246, United States
Contact Email: •••••@•••••
-
University Hospitals Cleveland Medical Center
RECRUITINGCleveland, Ohio, 44106, United States
Contact Email: •••••@•••••
-
University Medical Center & Texas Tech Health Science Center
RECRUITINGLubbock, Texas, 79430, United States
Contact Email: •••••@•••••
-
University of Arizona Cancer Center
RECRUITINGTucson, Arizona, 85719, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92093, United States
Contact Email: •••••@•••••
-
University of Colorado Anschutz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
Contact Email: •••••@•••••
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Email: •••••@•••••
-
University of Wisconsin - Carbone Cancer Center
RECRUITINGMadison, Wisconsin, 53705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Virginia Cancer Specialists
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
-
Yale - New Haven Hospital
RECRUITINGNew Haven, Connecticut, 06520, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.